IL300406A - Preparations and methods for the treatment or prevention of disease associated with beta corona virus infection - Google Patents

Preparations and methods for the treatment or prevention of disease associated with beta corona virus infection

Info

Publication number
IL300406A
IL300406A IL300406A IL30040623A IL300406A IL 300406 A IL300406 A IL 300406A IL 300406 A IL300406 A IL 300406A IL 30040623 A IL30040623 A IL 30040623A IL 300406 A IL300406 A IL 300406A
Authority
IL
Israel
Prior art keywords
ketotifen
nsaid
subject
administered
composition
Prior art date
Application number
IL300406A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sen Jam Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sen Jam Pharmaceutical Llc filed Critical Sen Jam Pharmaceutical Llc
Publication of IL300406A publication Critical patent/IL300406A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL300406A 2020-08-06 2021-08-06 Preparations and methods for the treatment or prevention of disease associated with beta corona virus infection IL300406A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063062138P 2020-08-06 2020-08-06
PCT/US2021/044897 WO2022032069A1 (en) 2020-08-06 2021-08-06 Compositions and methods for treating or preventing disease associated with beta coronavirus infection

Publications (1)

Publication Number Publication Date
IL300406A true IL300406A (en) 2023-04-01

Family

ID=80117684

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300406A IL300406A (en) 2020-08-06 2021-08-06 Preparations and methods for the treatment or prevention of disease associated with beta corona virus infection

Country Status (10)

Country Link
US (1) US20240033259A1 (https=)
EP (1) EP4192457B1 (https=)
JP (1) JP2023537369A (https=)
KR (1) KR20230048517A (https=)
CN (1) CN116322662A (https=)
AU (1) AU2021321535A1 (https=)
CA (1) CA3188387A1 (https=)
IL (1) IL300406A (https=)
MX (1) MX2023001570A (https=)
WO (1) WO2022032069A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046201A1 (en) 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION
CN116178373B (zh) * 2022-12-06 2024-06-18 南方科技大学 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180360811A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
WO2019046201A1 (en) * 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION

Also Published As

Publication number Publication date
EP4192457A1 (en) 2023-06-14
AU2021321535A1 (en) 2023-03-23
EP4192457A4 (en) 2024-09-18
MX2023001570A (es) 2023-05-03
CN116322662A (zh) 2023-06-23
WO2022032069A1 (en) 2022-02-10
CA3188387A1 (en) 2022-02-10
KR20230048517A (ko) 2023-04-11
JP2023537369A (ja) 2023-08-31
EP4192457B1 (en) 2026-03-25
US20240033259A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
US11135202B2 (en) Thiazolide compounds for treating viral infections
US20150018396A1 (en) Prevention and treatment of respiratory infection with peroxisome proliferator activator receptor delta agonist
EP3551187B1 (en) Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
JP7460772B2 (ja) コロナウイルス感染症の治療方法
WO2021169861A1 (zh) 核苷类化合物在治疗冠状病毒感染性疾病中的用途
US20240033259A1 (en) Compositions and methods for treating or preventing disease associated with beta coronavirus infection
MX2012014334A (es) Tratamiento de diabetes tipo 2.
US20180185404A1 (en) Compositions and methods for the treatment of viral infection
US10765630B2 (en) Methods and compositions to treat enteropathic arthritis
US20240115559A1 (en) Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
JP2019521160A (ja) C反応性タンパク質関連疾患の治療のための1−メチルニコチンアミド
US20230226066A1 (en) Compounds for the treatment of viral infections
US11654121B1 (en) Combination therapies for the treatment of viral infections
US20110045070A1 (en) Combination therapy
KR20220168172A (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물
JP2008239500A (ja) レプチン分泌促進剤
US20230301991A1 (en) Compounds for the treatment of viral infections
CN117838689A (zh) 培菲替尼在制备治疗流感病毒感染的药物中的应用
HK40102231A (zh) 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物
HK1199815A1 (en) Levocetirizine and montelukast for the treatment of influenza and common cold
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold